Imagion Biosystems Limited (ASX: IBX) (Imagion or the Company) is pleased to announce a pro-rata non- renounceable rights issue (Offer) to shareholders, on the basis of 1 new share for every 2 Imagion shares held as at 7.00pm (Melbourne time) Friday 28 September 2018 (Record Date).
View the Pro-Rata Non-Renounceable Rights Issue announcement.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer